Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in:

07-03-2025 | Nutrition Free for a limited time

Challenges to Optimizing Nutrition in Children With Cystic Fibrosis

Authors: Charles B. Chen, Jill A. Granneman, Sanu R. Yadav

Published in: Current Gastroenterology Reports | Issue 1/2025

Login to get access

Abstract

Purpose of Review

Cystic fibrosis is a chronic condition that has significant effects on the nutritional status of pediatric patients. Malnutrition is frequently encountered in this population and has been shown to contribute to poor pulmonary and overall disease outcomes. This article will provide an overview of the physiologic and psychosocial challenges toward attaining optimal nutrition in pediatric cystic fibrosis patients.

Recent Findings

Newer therapies such as CFTR modulators have played significant roles in improving the nutritional status of patients with cystic fibrosis. There is also a greater focus on becoming more aware of psychosocial and cultural barriers in the care of cystic fibrosis patients.

Summary

Many challenges exist in optimizing nutritional support including but not limited to the patient’s clinical manifestations and disease severity, caregiver ability, and access to care. Both gastrointestinal and non-gastrointestinal disorders lead to insufficient caloric intake, increased loss and metabolic needs, and micronutrient and macronutrient deficiency. Social factors including stressful patient and caregiver relationships and altered body image also contribute to poor nutritional status.
Literature
1.
Ashkenazi M, Nathan N, Sarouk I, Aluma BEB, Dagan A, Bezalel Y, et al. Nutritional status in childhood as a prognostic factor in patients with cystic fibrosis. Lung. 2019;197(3):371–6.PubMedCrossRef
2.
Culhane S, George C, Pearo B, Spoede E. Malnutrition in cystic fibrosis: a review. Nutr Clin Pract. 2013;28(6):676–83.PubMedCrossRef
3.
Mariotti Zani E, Grandinetti R, Cunico D, Torelli L, Fainardi V, Pisi G, et al. Nutritional care in children with cystic fibrosis. Nutrients. 2023;15(3):479.PubMedPubMedCentralCrossRef
4.
Madde A, Okoniewski W, Sanders DB, Ren CL, Weiner DJ, Forno E. Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis. J Cyst Fibros. 2022;21(5):769–76.PubMedCrossRef
5.
Nagy R, Gede N, Ocskay K, Dobai BM, Abada A, Vereczkei Z, et al. Association of body mass index with clinical outcomes in patients with cystic fibrosis: A systematic review and Meta-analysis. JAMA Netw Open. 2022;5(3):e220740.PubMedPubMedCentralCrossRef
6.
7.
Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator Ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–84.PubMedPubMedCentralCrossRef
8.
Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81.PubMedPubMedCentralCrossRef
9.
Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, et al. Impact of CFTR modulation with Ivacaftor on gut microbiota and intestinal inflammation. Sci Rep. 2018;8(1):17834.PubMedPubMedCentralCrossRef
10.
Patel D, Shan A, Mathews S, Sathe M. Understanding cystic fibrosis comorbidities and their impact on nutritional management. Nutrients. 2022;14(5):1028.PubMedPubMedCentralCrossRef
11.
Robinson NB, DiMango E. Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. Ann Am Thorac Soc. 2014;11(6):964–8.PubMedCrossRef
12.
Zazzeron L, Alicandro G, Daccò V, Lanfranchi C, Bulfamante A, Sciarrabba CS, et al. Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study. Dig Liver Dis. 2023;55(3):360–5.PubMedCrossRef
13.
Ayoub F, Lascano J, Morelli G. Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis. Gastroenterol Res. 2017;10(5):288–93.CrossRef
14.
Liu C, Bach TR, Farrell PM, Pavelec D, Antos NJ, Rock MJ, et al. Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2024;79(6):1124–33.PubMedPubMedCentralCrossRef
15.
Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg. 2007;42(8):1341–4.PubMedCrossRef
16.
Henen S, Denton C, Teckman J, Borowitz D, Patel D. Review of Gastrointestinal motility in cystic fibrosis. J Cyst Fibros. 2021;20(4):578–85.PubMedCrossRef
17.
Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and Gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 2013;58(8):2275–81.PubMedCrossRef
18.
Hedsund C, Gregersen T, Joensson IM, Olesen HV, Krogh K. Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol. 2012;47(8–9):920–6.PubMedCrossRef
19.
Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29(3):312–21.PubMedCrossRef
20.
McDonald CM, Reid EK, Pohl JF, Yuzyuk TK, Padula LM, Vavrina K, et al. Cystic fibrosis and fat malabsorption: pathophysiology of the cystic fibrosis Gastrointestinal tract and the impact of highly effective CFTR modulator therapy. Nutr Clin Pract. 2024;39(Suppl 1):S57–77.PubMed
21.
Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to < 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545–53.PubMedPubMedCentralCrossRef
22.
Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy balance and mechanisms of weight gain with Ivacaftor treatment of cystic fibrosis gating mutations. J Pediatr. 2018;201:229– 37.e4.
23.
Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162(11):760–3.PubMedCrossRef
24.
Phillips AE, Brownell JN, Tindall A, Kiernan BD, Patel D, Gelfond D, et al. Proton-pump inhibitors and fat absorption in cystic fibrosis and pancreatic insufficiency: a randomized crossover pilot trial. Dig Dis Sci. 2024.
25.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817–20.PubMedCrossRef
26.
Gifford AH, Sanville JL, Sathe M, Heltshe SL, Goss CH. Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis. Pediatr Pulmonol. 2021;56(7):2048–56.PubMedPubMedCentralCrossRef
27.
Efremova I, Maslennikov R, Poluektova E, Vasilieva E, Zharikov Y, Suslov A, et al. Epidemiology of small intestinal bacterial overgrowth. World J Gastroenterol. 2023;29(22):3400–21.PubMedPubMedCentralCrossRef
28.
Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–70.PubMedCrossRef
29.
Gabel ME, Wang H, Gelfond D, Roach C, Rowe SM, Clancy JP, et al. Changes in glucose breath test in cystic fibrosis patients treated with 1 month of Lumacaftor/Ivacaftor. J Pediatr Gastroenterol Nutr. 2022;75(1):42–7.PubMedCrossRef
30.
Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, et al. Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros. 2022;21(2):e141–7.PubMedCrossRef
31.
Yeomans MR. Olfactory influences on appetite and satiety in humans. Physiol Behav. 2006;87(4):800–4.PubMedCrossRef
32.
Di Lullo AM, Iacotucci P, Comegna M, Amato F, Dolce P, Castaldo G, et al. Cystic fibrosis: the sense of smell. Am J Rhinol Allergy. 2020;34(1):35–42.PubMedCrossRef
33.
McTavish D, Thornton J. Appetite stimulants for people with cystic fibrosis. Cochrane Database Syst Rev. 2022;9(9):CD008190.PubMed
34.
Epifanio M, Marostica PC, Mattiello R, Feix L, Nejedlo R, Fischer GB. A randomized, double-blind, placebo-controlled trial of Cyproheptadine for appetite stimulation in cystic fibrosis. J Pediatr (Rio J). 2012;88(2):155–60.PubMedCrossRef
35.
Grunert J, van der Haak N, La Vanda C, Farrow N, Tai A. Cyproheptadine as an appetite stimulant in children with cystic fibrosis. Clin Nutr ESPEN. 2021;42:407–9.PubMedCrossRef
36.
Gaschignard M, Beaufils F, Lussac-Sorton F, Gallet P, Clouzeau H, Menard J, et al. Nutritional impact of CFTR modulators in children with cystic fibrosis. Front Pediatr. 2023;11:1130790.PubMedPubMedCentralCrossRef
37.
38.
Sutherland R, Katz T, Liu V, Quintano J, Brunner R, Tong CW, et al. Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis. J Cyst Fibros. 2018;17(6):804–10.PubMedCrossRef
39.
Bellissimo MP, Zhang I, Ivie EA, Tran PH, Tangpricha V, Hunt WR, et al. Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis. J Cyst Fibros. 2019;18(3):430–5.PubMedPubMedCentralCrossRef
40.
Greaney C, Doyle A, Drummond N, King S, Hollander-Kraaijeveld F, Robinson K, et al. What do people with cystic fibrosis eat? Diet quality, macronutrient and micronutrient intakes (compared to recommended guidelines) in adults with cystic fibrosis-A systematic review. J Cyst Fibros. 2023;22(6):1036–47.PubMedCrossRef
41.
Rana M, Wong-See D, Katz T, Gaskin K, Whitehead B, Jaffe A, et al. Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis. J Clin Pathol. 2014;67(7):605–8.PubMedCrossRef
42.
Francalanci M, Terlizzi V, Fevola C, Di Rosa G, Pierattini V, Roselli E, et al. Nutritional status and Circulating levels of Fat-Soluble vitamins in cystic fibrosis patients: A cohort study and evaluation of the effect of CFTR modulators. Child (Basel). 2023;10(2):252.
43.
Schembri L, Warraich S, Bentley S, Carr SB, Balfour-Lynn IM. Impact of Elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis. J Cyst Fibros. 2023;22(5):843–6.PubMedCrossRef
44.
Hergenroeder GE, Faino A, Bridges G, Bartlett LE, Cogen JD, Green N, et al. The impact of Elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1048–53.PubMedPubMedCentralCrossRef
45.
Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H, et al. Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight. Mol Cell Pediatr. 2024;11(1):4.PubMedPubMedCentralCrossRef
46.
Sankararaman S, Schindler T, Sferra TJ. Management of exocrine pancreatic insufficiency in children. Nutr Clin Pract. 2019;34(Suppl 1):S27–42.PubMed
47.
Schall JI, Bentley T, Stallings VA. Meal patterns, dietary fat intake and pancreatic enzyme use in preadolescent children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2006;43(5):651–9.PubMedCrossRef
48.
Borschuk AP, Filigno SS, Opipari-Arrigan L, Peugh J, Stark LJ. Psychological predictors of nutritional adherence in adolescents with cystic fibrosis. Clin Nutr ESPEN. 2019;33:143–7.PubMedPubMedCentralCrossRef
49.
Bishay LC, Sawicki GS. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016;7:117–24.PubMedPubMedCentral
50.
Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health. 2006;38(1):13–7.PubMedCrossRef
51.
52.
Marciel KK, Saiman L, Quittell LM, Dawkins K, Quittner AL. Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol. 2010;45(2):157–64.PubMedPubMedCentralCrossRef
53.
Boon M, Calvo-Lerma J, Claes I, Havermans T, Asseiceira I, Bulfamante A, et al. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with cystic fibrosis. J Cyst Fibros. 2020;19(4):562–8.PubMedCrossRef
54.
Longacre M, Grande S, Hager A, Montan M, Bergquist RP, Martensson M, et al. Clinical adoption of mHealth technology to support pediatric cystic fibrosis care in Sweden: qualitative case study. JMIR Pediatr Parent. 2018;1(2):e11080.PubMedPubMedCentralCrossRef
55.
Zientek E, Rane S, Godfrey C, Sisson A, Dickinson KM. Factors guiding gastrostomy tube decision-making for caregivers of children with cystic fibrosis: a scoping review protocol. BMJ Open. 2023;13(12):e076539.PubMedPubMedCentralCrossRef
56.
Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013;162(3):530–e51.PubMedCrossRef
57.
Schwarzenberg SJ, Hempstead SE, McDonald CM, Powers SW, Wooldridge J, Blair S, et al. Enteral tube feeding for individuals with cystic fibrosis: cystic fibrosis foundation evidence-informed guidelines. J Cyst Fibros. 2016;15(6):724–35.PubMedCrossRef
58.
Sullivan JS, Mascarenhas MR, Nutrition. Prevention and management of nutritional failure in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S87–93.PubMedCrossRef
59.
Freedman S. Options for addressing exocrine pancreatic insufficiency in patients receiving enteral nutrition supplementation. Am J Manag Care. 2017;23(12 Suppl):S220–8.PubMed
60.
Stevens J, Wyatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and safety with sustained use of relizorb evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding. J Pediatr Gastroenterol Nutr. 2018;67(4):527–32.PubMedPubMedCentralCrossRef
61.
Shrivastava S, Shaw K, Lee M, Reitich P, Hunter S, Klosterman M, et al. Association of in-line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis. Nutr Clin Pract. 2024;39(4):903–10.PubMedCrossRef
62.
Hendrix SJ, Flume PA, First ER, Stone AA, Van Buskirk M. Improvements in anthropometric measures and Gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutr Clin Pract. 2022;37(2):344–50.PubMedPubMedCentralCrossRef
63.
McDonald C, Christensen N, Lingard C, Peet K, Walker S. Nutrition knowledge and confidence levels of parents of children with cystic fibrosis. ICAN. 2009;1:325–31.
64.
Corbera-Hincapie MA, Atteih SE, Stransky OM, Weiner DJ, Yann IM, Kazmerski TM. Experiences and perspectives of individuals with cystic fibrosis and their families related to food insecurity. Nutrients. 2022;14(13):2573.PubMedPubMedCentralCrossRef
65.
Klinger KW. Cystic fibrosis in the Ohio Amish: gene frequency and founder effect. Hum Genet. 1983;65(2):94–8.PubMedCrossRef
66.
67.
Darukhanavala A, Merjaneh L, Mason K, Le T. Eating disorders and body image in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100280.PubMedPubMedCentral
68.
Raymond NC, Chang PN, Crow SJ, Mitchell JE, Dieperink BS, Beck MM, et al. Eating disorders in patients with cystic fibrosis. J Adolesc. 2000;23(3):359–63.PubMedCrossRef
69.
Petropoulou A, Bakounaki G, Grammatikopoulou MG, Bogdanos DP, Goulis DG, Vassilakou T. Eating disorders and disordered eating behaviors in cystic fibrosis: A neglected issue. Child (Basel). 2022;9(6):915.
70.
Shearer JE, Bryon M. The nature and prevalence of eating disorders and eating disturbance in adolescents with cystic fibrosis. J R Soc Med. 2004;97(Suppl 44):36–42.PubMedPubMedCentral
71.
Tran JK, Ooi CY, Blazek K, Katz T. Body composition and body mass index measures from 8 to 18 years old in children with cystic fibrosis. J Cyst Fibros. 2023;22(5):851–6.PubMedCrossRef
72.
Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022;21(5):777–83.PubMedPubMedCentralCrossRef
73.
74.
Kass AP, Kazmerski TM, Bern E, Sabharwal S, Leonard J, Harrison M, et al. Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 2023;22(3):431–5.PubMedCrossRef
75.
Sanders MR, Gravestock FM, Wanstall K, Dunne M. The relationship between children’s treatment-related behaviour problems, age and clinical status in cystic fibrosis. J Paediatr Child Health. 1991;27(5):290–4.PubMedCrossRef
76.
Ellis JM, Galloway AT, Webb RM, Martz DM, Farrow CV. Recollections of pressure to eat during childhood, but not picky eating, predict young adult eating behavior. Appetite. 2016;97:58–63.PubMedCrossRef
77.
Maliszewski G, High R, Lee J, Deschamp A. Parental feeding style, parenting stress, and child mealtime behaviors in cystic fibrosis. J Pediatr Psychol. 2024;49(1):56–65.PubMedCrossRef
78.
Powers SW, Mitchell MJ, Patton SR, Byars KC, Jelalian E, Mulvihill MM, et al. Mealtime behaviors in families of infants and toddlers with cystic fibrosis. J Cyst Fibros. 2005;4(3):175–82.PubMedCrossRef
79.
Abbott J, Conway S, Etherington C, Fitzjohn J, Gee L, Morton A, et al. Perceived body image and eating behavior in young adults with cystic fibrosis and their healthy peers. J Behav Med. 2000;23(6):501–17.PubMedCrossRef
80.
Egan H, Keyte R, Mantzios M. The challenges of eating well for people living with cystic fibrosis: an interview study exploring the use of mindful eating approaches and behaviours to support optimal nutritional status. Int J Behav Med. 2022;29(6):762–74.PubMedPubMedCentralCrossRef
81.
Stice E. Interactive and mediational etiologic models of eating disorder onset: evidence from prospective studies. Annu Rev Clin Psychol. 2016;12:359–81.PubMedCrossRef
82.
Tort-Nasarre G, Pollina Pocallet M, Artigues-Barberà E. The meaning and factors that influence the concept of body image: systematic review and Meta-Ethnography from the perspectives of adolescents. Int J Environ Res Public Health. 2021;18(3):1140.PubMedPubMedCentralCrossRef
83.
Pinquart M. Body image of children and adolescents with chronic illness: a meta-analytic comparison with healthy peers. Body Image. 2013;10(2):141–8.PubMedCrossRef
84.
85.
Levinson JA, Kinkel-Ram S, Myers B, Hunger JM. A systematic review of weight stigma and disordered eating cognitions and behaviors. Body Image. 2024;48:101678.PubMedPubMedCentralCrossRef
86.
Lyons ER, Muther E, Sabharwal S. Nutrition and behavioral health in cystic fibrosis: eating and body image. Pediatr Pulmonol. 2024;59(Suppl 1):S36–43.PubMed
87.
Helms SW, Christon LM, Dellon EP, Prinstein MJ. Patient and provider perspectives on communication about body image with adolescents and young adults with cystic fibrosis. J Pediatr Psychol. 2017;42(9):1040–50.PubMedCrossRef
88.
Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians’ views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;22(5):836–42.PubMedCrossRef
Metadata
Title
Challenges to Optimizing Nutrition in Children With Cystic Fibrosis
Authors
Charles B. Chen
Jill A. Granneman
Sanu R. Yadav
Publication date
07-03-2025

Other articles of this Issue 1/2025

Rectal Prolapse in the Pediatric Population

Decoding abdominal pain in IBS-C and functional constipation

Sexual wellbeing and intimacy in IBD

A Review of Exocrine Pancreatic Insufficiency in Children beyond Cystic Fibrosis and the Role of Endoscopic Direct Pancreatic Function Testing

Global Prevalence of Anxiety in Gastroenterology and Hepatology Outpatients: A Systematic Review and Meta-Analysis

Virtual Reality and Augmented Reality Use Cases in Gastroenterology

Image Credits